首页> 美国卫生研究院文献>Translational Lung Cancer Research >Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy proton therapy and stereotactic body radiation therapy
【2h】

Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy proton therapy and stereotactic body radiation therapy

机译:非小细胞肺癌放疗技术和分娩的进展:调强放射疗法质子疗法和立体定向放射疗法的益处

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The 21st century has seen several paradigm shifts in the treatment of non-small cell lung cancer (NSCLC) in early-stage inoperable disease, definitive locally advanced disease, and the postoperative setting. A key driver in improvement of local disease control has been the significant evolution of radiation therapy techniques in the last three decades, allowing for delivery of definitive radiation doses while limiting exposure of normal tissues. For patients with locally-advanced NSCLC, the advent of volumetric imaging techniques has allowed a shift from 2-dimensional approaches to 3-dimensional conformal radiation therapy (3DCRT). The next generation of 3DCRT, intensity-modulated radiation therapy and volumetric-modulated arc therapy (VMAT), have enabled even more conformal radiation delivery. Clinical evidence has shown that this can improve the quality of life for patients undergoing definitive management of lung cancer. In the early-stage setting, conventional fractionation led to poor outcomes. Evaluation of altered dose fractionation with the previously noted technology advances led to advent of stereotactic body radiation therapy (SBRT). This technique has dramatically improved local control and expanded treatment options for inoperable, early-stage patients. The recent development of proton therapy has opened new avenues for improving conformity and the therapeutic ratio. Evolution of newer proton therapy techniques, such as pencil-beam scanning (PBS), could improve tolerability and possibly allow reexamination of dose escalation. These new progresses, along with significant advances in systemic therapies, have improved survival for lung cancer patients across the spectrum of non-metastatic disease. They have also brought to light new challenges and avenues for further research and improvement.
机译:在21世纪,非小细胞肺癌(NSCLC)在早期无法手术的疾病,确定的局部晚期疾病和术后环境中的治疗方式发生了一些转变。过去三十年来,改善局部疾病控制的关键驱动因素是放射治疗技术的显着发展,可以在确定放射剂量的同时限制正常组织的暴露。对于局部晚期NSCLC患者,体积成像技术的出现使人们从二维方法转向了三维保形放射治疗(3DCRT)。下一代3DCRT,强度调制放射疗法和体积调制弧光疗法(VMAT)已实现了更多的保形放射递送。临床证据表明,这可以改善接受明确治疗的肺癌患者的生活质量。在早期阶段,常规分馏导致不良结果。随着先前提到的技术进步对剂量分数变化的评估,导致了立体定向放射治疗(SBRT)的问世。这项技术极大地改善了无法控制的早期患者的局部控制并扩大了治疗选择。质子疗法的最新发展为改善顺应性和治疗率开辟了新途径。较新的质子治疗技术的发展,例如笔形束扫描(PBS),可以改善耐受性,并可能允许重新检查剂量递增。这些新进展以及全身疗法的重大进展,已提高了肺癌患者在非转移性疾病范围内的生存率。它们还为进一步研究和改进提供了新的挑战和途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号